Author:
Visintini Chiara,Lucchetta Chiara,Venturini Margherita,Mansutti Irene,Chiappinotto Stefania,Patriarca Francesca,Palese Alvisa
Abstract
Abstract
Purpose
Despite the importance of adherence to immunosuppressants (IMMs) after an allogeneic haematopoietic stem cell transplant (HSCT) for the treatment of acute graft-versus-host disease (aGvHD), no studies to date have reported the experiences of such patients concerning medication adherence (MA). Therefore, the aim of the study was to explore the perspective on MA to immunosuppressive oral therapy among allogeneic HSCT patients with aGvHD.
Methods
A qualitative descriptive study following a reflexive thematic analysis methodological approach was performed involving a purposive sample of 16 patients with aGvHD who were being cared for in the outpatient setting of a bone marrow transplant centre and were willing to participate. Semi-structured audio-recorded interviews were conducted, transcribed verbatim and thematically analysed; member checking was performed. COnsolidated criteria for REporting Qualitative research (COREQ) and the ESPACOMP Medication Adherence Reporting Guideline were followed.
Results
Participants aged 25–74 years and mostly males (62.5%) were recruited for this study; 56.2% developed grade I, 37.5% grade II and 6.3% grade III aGvHD; 56.2% were receiving treatment with both cyclosporine and prednisone. Patients' perspectives have been summarised into four themes, named: “Transiting from an external obligation to a habit”; “Being in the middle between the negative and positive effects of the IMMs”; “Failure to systematically respect the rules”; and “Adopting personal strategies to become adherent”. After difficulties with the perception of feeling obliged, patients became used to adhering to IMMs. Although there were failures in systematically taking the medication correctly and there were episodes of non-adherence, the adoption of personal strategies helped patients to become adherent to their medication schedules.
Conclusions
MA in patients with aGvHD is a complex behaviour and is often a challenge. These results can help healthcare professionals and centres to understand how best to design tailored strategies and behavioural interventions to maximise patients’ MA to IMMs.
Funder
Università degli Studi di Roma Tor Vergata
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Passweg JR, Baldomero H, Ciceri F et al (2024) Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplant. https://doi.org/10.1038/s41409-024-02248-9
2. Penack O, Marchetti M, Ruutu T et al (2020) Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 7(2):e157–e167. https://doi.org/10.1016/S2352-3026(19)30256-X
3. Maurer K, Soiffer RJ (2023) The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. https://doi.org/10.1080/17474086.2023.2273847
4. Carreras E, Styczynski J, Ljungman P (2024) HCT complications and management. In: Sureda A, Corbacioglu S, Greco R, Kröger N, Carreras E (eds) The EBMT Handbook. Hematopoietic Cell Transplantation and Cellular therapies, 2nd edn, Springer, Cham, pp 311–344
5. Zeiser R, Blazar BR (2017) Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 377(22):2167–2179. https://doi.org/10.1056/NEJMra1609337